Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting

The Prostate Cancer Foundation (PCF) convened a PCF prostate‐specific membrane antigen (PSMA) Theranostics State of the Science Meeting on 18 November 2019, at Weill Cornell Medicine, New York, NY.

[1]  T. Powles,et al.  Abstract CT014: IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC) , 2020 .

[2]  S. Vallabhajosula,et al.  Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer. , 2020, Urologic oncology.

[3]  E. Berns,et al.  CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer , 2020, Nature Communications.

[4]  M. Morris,et al.  Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial. , 2020 .

[5]  Steve Y. Cho,et al.  Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR). , 2020 .

[6]  M. Stockler,et al.  TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603). , 2020 .

[7]  S. Vallabhajosula,et al.  Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC). , 2020 .

[8]  J. Czernin,et al.  Overall survival after 177Lu-PSMA-617 molecular radiotherapy in patients with metastatic castrate-resistant prostate cancer: Post-hoc analysis of a prospective phase II trial. , 2020 .

[9]  A. Kishan,et al.  PSMA Expression in the Neovasculature Associated With Rectal Adenocarcinoma: A Potential Stromal Target for Nuclear Theranostics. , 2020, Clinical nuclear medicine.

[10]  F. Saad,et al.  Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[11]  N. Agarwal,et al.  CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. , 2020, JCO precision oncology.

[12]  A. Chinnaiyan,et al.  CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. , 2020, JCO Precision Oncology.

[13]  P. Kantoff,et al.  Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. , 2020, European urology.

[14]  M. Hofman,et al.  Mechanistic Insights for Optimizing PSMA Radioligand Therapy , 2020, Clinical Cancer Research.

[15]  Ash A. Alizadeh,et al.  Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer , 2020, JAMA oncology.

[16]  N. Lawrentschuk,et al.  Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study , 2020, The Lancet.

[17]  C. Buchpiguel,et al.  Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings , 2020, Cancer Imaging.

[18]  D. Murphy,et al.  Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617 , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  S. Vallabhajosula,et al.  Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC). , 2020 .

[20]  E. Antonarakis,et al.  Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5. , 2020 .

[21]  C. Drake,et al.  Randomized phase II study of sipuleucel-T (SipT) with or without radium-223 (Ra223) in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC). , 2020 .

[22]  U. Haberkorn,et al.  225Ac-PSMA-617 for Therapy of Prostate Cancer. , 2020, Seminars in nuclear medicine.

[23]  D. Murphy,et al.  Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer , 2020, Nature Reviews Urology.

[24]  J. Czernin,et al.  Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity , 2020, Clinical Cancer Research.

[25]  C. Chargari,et al.  Radiobiology: Foundation and New Insights in Modeling Brachytherapy Effects. , 2020, Seminars in radiation oncology.

[26]  N. Lawrentschuk,et al.  Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. , 2020, European urology.

[27]  R. Hicks,et al.  Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors , 2019, The Journal of Nuclear Medicine.

[28]  N. Tunariu,et al.  Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial , 2019, The Lancet. Oncology.

[29]  C. Drake,et al.  Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Murphy,et al.  Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer , 2019, The Journal of Nuclear Medicine.

[31]  M. O’Connor,et al.  AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity , 2019, Nature Communications.

[32]  P. Choyke,et al.  18F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy , 2019, The Journal of Nuclear Medicine.

[33]  J. Miśko,et al.  Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer. , 2019, Clinical nuclear medicine.

[34]  A. Drzezga,et al.  Intraindividual Comparison of 18F-PSMA-1007 with Renally Excreted PSMA Ligands for PSMA PET Imaging in Patients with Relapsed Prostate Cancer , 2019, The Journal of Nuclear Medicine.

[35]  M. Hofman,et al.  Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies , 2019, Prostate Cancer and Prostatic Diseases.

[36]  A. Maes,et al.  PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review , 2019, International journal of molecular sciences.

[37]  H. Beltran,et al.  Preliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC) , 2019, Annals of Oncology.

[38]  A. Bryce,et al.  Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses , 2019, Annals of Oncology.

[39]  N. Lawrentschuk,et al.  Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team , 2019, BJU international.

[40]  J. Carles,et al.  Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.

[41]  R. Pearson,et al.  PARP inhibitor and CX-5461 combination therapy as a novel treatment strategy for castrate-resistant prostate cancer , 2019, Oncology Abstracts.

[42]  M. O’Connor,et al.  Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically , 2019, Molecular Cancer Therapeutics.

[43]  Roger Slavik,et al.  18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. , 2019, The Lancet. Oncology.

[44]  H. Beltran,et al.  Phase 1/2 study of fractionated dose lutetium‐177–labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer , 2019, Cancer.

[45]  O. Elemento,et al.  Abstract 4865: Prognostic value of BRCA2 and AR gene alterations in advanced prostate cancer patients treated with PSMA-targeted radionuclide therapies , 2019, Clinical Research (Excluding Clinical Trials).

[46]  K. Pienta,et al.  Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls. , 2019, Seminars in nuclear medicine.

[47]  W. Weber,et al.  Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy , 2019, The Journal of Nuclear Medicine.

[48]  T. Akhurst,et al.  Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[49]  P. Carroll,et al.  Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. , 2019, JAMA oncology.

[50]  M. Schwaiger,et al.  Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. , 2019, European urology.

[51]  L. Collette,et al.  Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis. , 2019, Journal of Clinical Oncology.

[52]  N. Bander,et al.  Association of noninvasive, radiographic measurement of prostate-specific membrane antigen (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT). , 2019, Journal of Clinical Oncology.

[53]  B. Goh,et al.  First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. , 2019, Journal of Clinical Oncology.

[54]  J. Czernin,et al.  RESIST-PC phase 2 trial: 177Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer. , 2019, Journal of Clinical Oncology.

[55]  John O. Prior,et al.  Detection Rate of 18F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis , 2019, Cancers.

[56]  S. Gregory,et al.  Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  F. Saad,et al.  Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[58]  M. Galsky,et al.  Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650). , 2019, Journal of Clinical Oncology.

[59]  O. Elemento,et al.  Clinical and molecular analysis of patients treated with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy. , 2019, Journal of Clinical Oncology.

[60]  Jing Wang,et al.  Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. , 2019, Cancer discovery.

[61]  T. Tammela,et al.  Darolutamide in Nonmetastatic, Castration‐Resistant Prostate Cancer , 2019, The New England journal of medicine.

[62]  J. Lunceford,et al.  T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  W. Vach,et al.  Detection Rate of 18F-Choline PET/CT and 68Ga-PSMA-HBED-CC PET/CT for Prostate Cancer Lymph Node Metastases with Direct Link from PET to Histopathology: Dependence on the Size of Tumor Deposits in Lymph Nodes , 2019, The Journal of Nuclear Medicine.

[64]  T. Esen,et al.  Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer? , 2018, Nuclear medicine communications.

[65]  D. Murphy,et al.  Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy. , 2019, European urology oncology.

[66]  L. Lacombe,et al.  Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration. , 2019, European urology focus.

[67]  D. Elashoff,et al.  Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT] , 2019, BMC Cancer.

[68]  P. Choyke,et al.  A comparison of prostate cancer bone metastases on 18F-Sodium Fluoride and Prostate Specific Membrane Antigen (18F-PSMA) PET/CT: Discordant uptake in the same lesion , 2018, Oncotarget.

[69]  R. Epstein,et al.  Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial 68Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade , 2018, The Journal of Nuclear Medicine.

[70]  James M. Kelly,et al.  A Single Dose of 225Ac-RPS-074 Induces a Complete Tumor Response in an LNCaP Xenograft Model , 2018, The Journal of Nuclear Medicine.

[71]  A. Sasikumar,et al.  Gallium 68-PSMA PET/CT for lesion characterization in suspected cases of prostate carcinoma , 2018, Nuclear medicine communications.

[72]  J. Czernin,et al.  Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer , 2018, EJNMMI Research.

[73]  D. Murphy,et al.  Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes , 2018, The Journal of Nuclear Medicine.

[74]  H. Beltran,et al.  Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC). , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[75]  Steven P. Rowe,et al.  Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging , 2018, The Journal of Nuclear Medicine.

[76]  Matthias Eiber,et al.  68Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging , 2018, The Journal of Nuclear Medicine.

[77]  K. Pienta,et al.  Meeting report from the Prostate Cancer Foundation PSMA‐directed radionuclide scientific working group , 2018, The Prostate.

[78]  C. Seymour,et al.  Radiation fractionation: the search for isoeffect relationships and mechanisms , 2018, International journal of radiation biology.

[79]  P. Choyke,et al.  Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy , 2018, The Journal of Nuclear Medicine.

[80]  A. Chiti,et al.  68Ga‐PSMA Positron Emission Tomography/Computerized Tomography for Primary Diagnosis of Prostate Cancer in Men with Contraindications to or Negative Multiparametric Magnetic Resonance Imaging: A Prospective Observational Study , 2018, The Journal of urology.

[81]  V. Velculescu,et al.  Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer , 2018, Oncotarget.

[82]  Tomas Kron,et al.  Deep Learning Renal Segmentation for Fully Automated Radiation Dose Estimation in Unsealed Source Therapy , 2018, Front. Oncol..

[83]  D. Murphy,et al.  [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. , 2018, The Lancet. Oncology.

[84]  A. Chinnaiyan,et al.  Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer , 2018, Cell.

[85]  M. Javadi,et al.  Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms , 2018, The Journal of Nuclear Medicine.

[86]  L. Domachevsky,et al.  Quantitative characterisation of clinically significant intra-prostatic cancer by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11 , 2018, European Radiology.

[87]  P. Choyke,et al.  Evaluation of PSMA-based 18F-DCFPyL PET/CT imaging in patients with biochemical recurrence prostate cancer after primary local therapy , 2018 .

[88]  M. Morris,et al.  Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial , 2018, JAMA oncology.

[89]  James M. Kelly,et al.  Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[90]  P. Choyke,et al.  A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer , 2018, The Journal of Nuclear Medicine.

[91]  K. Rahbar,et al.  Advantage of 18F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[92]  F. Saad,et al.  Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer , 2018, The New England journal of medicine.

[93]  H. Hieronymus,et al.  Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors , 2018, The Journal of experimental medicine.

[94]  E. Goetghebeur,et al.  Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  Steven P Rowe,et al.  PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies. , 2017, European urology.

[96]  Steven P Rowe,et al.  Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen–Targeted PET Imaging: PSMA-RADS Version 1.0 , 2017, The Journal of Nuclear Medicine.

[97]  K. Pienta,et al.  Prostate Specific Membrane Antigen Targeted 18F‐DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study , 2018, The Journal of urology.

[98]  K. Rahbar,et al.  Targeting PSMA by radioligands in non-prostate disease—current status and future perspectives , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[99]  Nirbhay N. Yadav,et al.  A dextran-based probe for the targeted magnetic resonance imaging of tumours expressing prostate-specific membrane antigen , 2017, Nature Biomedical Engineering.

[100]  Steven P Rowe,et al.  Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy , 2017, The Journal of Nuclear Medicine.

[101]  R. Bundschuh,et al.  Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer , 2017, Oncotarget.

[102]  Matthias Eiber,et al.  177Lu-PSMA Radioligand Therapy for Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[103]  Frederik L. Giesel,et al.  68Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters , 2017, The Journal of Nuclear Medicine.

[104]  A. Drzezga,et al.  PSA-Stratified Performance of 18F- and 68Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[105]  N. Lawrentschuk,et al.  Utility of 68Ga prostate specific membrane antigen – positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma , 2017, Journal of medical imaging and radiation oncology.

[106]  G. Salles,et al.  Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. , 2017, Blood.

[107]  James M. Kelly,et al.  Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[108]  W. Vach,et al.  Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer , 2017, Theranostics.

[109]  S. Bhutra,et al.  Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers , 2017, Oncotarget.

[110]  Baris Turkbey,et al.  Accuracy and agreement of PIRADSv2 for prostate cancer mpMRI: A multireader study , 2017, Journal of magnetic resonance imaging : JMRI.

[111]  Clemens Decristoforo,et al.  68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[112]  W. Brenner,et al.  German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients , 2017, Journal of Nuclear Medicine.

[113]  G. Böning,et al.  Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer , 2016, Oncotarget.

[114]  F. Saad,et al.  Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  G. Cheon,et al.  Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges , 2017, Nuclear Medicine and Molecular Imaging.

[116]  Danny F. Martinez,et al.  First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake , 2016, The Journal of Nuclear Medicine.

[117]  H. Jadvar.  Is There Use for FDG-PET in Prostate Cancer? , 2016, Seminars in nuclear medicine.

[118]  P. Nelson,et al.  Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate , 2016, Oncotarget.

[119]  Oliver Sartor,et al.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  C. V. van Eijck,et al.  Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib , 2016, Theranostics.

[121]  Charles G. Drake,et al.  Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer , 2016, Oncotarget.

[122]  F. Mottaghy,et al.  225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[123]  Ahmet Zehir,et al.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. , 2016, The New England journal of medicine.

[124]  K. Rahbar,et al.  Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer , 2016, Clinical nuclear medicine.

[125]  M. Morris,et al.  Updated results: A phase I/IIa randomized trial of radium-223 + docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases. , 2016 .

[126]  Markus Schwaiger,et al.  Current use of PSMA–PET in prostate cancer management , 2016, Nature Reviews Urology.

[127]  J. Babich,et al.  Preliminary evaluation of prostate‐targeted radiotherapy using 131I‐MIP‐1095 in combination with radiosensitising chemotherapeutic drugs , 2016, The Journal of pharmacy and pharmacology.

[128]  T. Derlin,et al.  68Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging , 2016, European Radiology.

[129]  M. Ferrari,et al.  18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[130]  R. Fimmers,et al.  Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer , 2016, Oncotarget.

[131]  K. Pienta,et al.  PSMA-Based Detection of Prostate Cancer Bone Lesions With ¹⁸F-DCFPyL PET/CT: A Sensitive Alternative to (⁹⁹m)Tc-MDP Bone Scan and Na¹⁸F PET/CT? , 2016, Clinical genitourinary cancer.

[132]  Xiangshi Tan,et al.  Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response , 2016, Scientific Reports.

[133]  Keith F. Eckerman,et al.  MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy , 2016, The Journal of Nuclear Medicine.

[134]  Wei Yuan,et al.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.

[135]  M. Pomper,et al.  Synthesis and Evaluation of Gd(III) -Based Magnetic Resonance Contrast Agents for Molecular Imaging of Prostate-Specific Membrane Antigen. , 2015, Angewandte Chemie.

[136]  S. Fanti,et al.  Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy , 2015, The Journal of Nuclear Medicine.

[137]  Danny F. Martinez,et al.  A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer , 2015, Clinical Cancer Research.

[138]  David C. Smith,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[139]  U. Haberkorn,et al.  Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer , 2015, The Journal of Nuclear Medicine.

[140]  A. Drzezga,et al.  Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer , 2015, Molecular Imaging and Biology.

[141]  P. Kantoff,et al.  Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[143]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[144]  U. Haberkorn,et al.  Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[145]  M. Pomper,et al.  Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer , 2014, Clinical Cancer Research.

[146]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[147]  R. Weichselbaum,et al.  STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. , 2014, Immunity.

[148]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[149]  N. Agarwal,et al.  Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[150]  S. Fosså,et al.  Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. , 2014, The Lancet. Oncology.

[151]  H. Beltran,et al.  Phase I trial of docetaxel/prednisone plus fractionated dose radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody 177lu-J591 in patients with metastatic, castration-resistant prostate cancer (mCRPC). , 2014 .

[152]  R. Coleman,et al.  Impact of 18F-Fluoride PET in Patients with Known Prostate Cancer: Initial Results from the National Oncologic PET Registry , 2014, The Journal of Nuclear Medicine.

[153]  B. Hadaschik,et al.  Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[154]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[155]  A. Hogg,et al.  An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging. , 2013, Medical physics.

[156]  F. Feng,et al.  A hormone-DNA repair circuit governs the response to genotoxic insult. , 2013, Cancer discovery.

[157]  H. Hieronymus,et al.  Androgen receptor signaling regulates DNA repair in prostate cancers. , 2013, Cancer discovery.

[158]  S. Vallabhajosula,et al.  Bone Marrow Recovery and Subsequent Chemotherapy Following Radiolabeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Men with Metastatic Castration-Resistant Prostate Cancer , 2013, Front. Oncol..

[159]  A. Sanchez-Crespo,et al.  Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. , 2013, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[160]  Stanley J. Goldsmith,et al.  Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer , 2013, Clinical Cancer Research.

[161]  E. Basch,et al.  Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. , 2012, The Lancet. Oncology.

[162]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[163]  M. Bernstein,et al.  In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer , 2012, Front. Oncol..

[164]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[165]  U. Haberkorn,et al.  68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. , 2012, Bioconjugate chemistry.

[166]  A. Ashworth,et al.  The DNA damage response and cancer therapy , 2012, Nature.

[167]  Annie Gao,et al.  Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. , 2012, The Lancet. Oncology.

[168]  J. Hendry,et al.  Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. , 2012, International journal of radiation oncology, biology, physics.

[169]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[170]  R. Katz.  FDA: Evidentiary standards for drug development and approval , 2004, NeuroRX.

[171]  R. Hicks,et al.  The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[172]  E. D. de Vries,et al.  Trastuzumab pharmacokinetics influenced by extent human epidermal growth factor receptor 2-positive tumor load. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[173]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[174]  Christof Baltes,et al.  A portable albumin binder from a DNA-encoded chemical library. , 2008, Angewandte Chemie.

[175]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[176]  A Daşu,et al.  Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? , 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

[177]  S. Larson,et al.  Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors , 2007, Clinical Cancer Research.

[178]  S. Vallabhajosula,et al.  Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[179]  Shankar Vallabhajosula,et al.  Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[180]  S. Vallabhajosula,et al.  Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[181]  S. Vallabhajosula,et al.  Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[182]  G. Chodak,et al.  The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy. , 2004, The Journal of urology.

[183]  A. Chalmers.  Poly(ADP-ribose) polymerase-1 and ionizing radiation: sensor, signaller and therapeutic target. , 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).

[184]  N. Bander,et al.  Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. , 2003, The Journal of urology.

[185]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[186]  J. Neale,et al.  Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). , 2001, Journal of medicinal chemistry.

[187]  R L Sokoloff,et al.  A dual‐monoclonal sandwich assay for prostate‐specific membrane antigen: Levels in tissues, seminal fluid and urine , 2000, The Prostate.

[188]  V. Reuter,et al.  Prostate-specific membrane antigen is produced in tumor-associated neovasculature. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[189]  N. Bander,et al.  Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. , 1997, Cancer research.

[190]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.